BioNTech reported Q3 2024 revenues of €1.2 billion, up from €895.3 million in Q3 2023, driven by earlier approvals of variant-adapted COVID-19 vaccines. Net profit reached €198.1 million with diluted EPS of €0.81. The company expects full-year 2024 revenues to be at the low end of €2.5-3.1 billion guidance range.The company advanced its oncology pipeline with multiple clinical trials, including two Phase 2 dose optimization studies for BNT327/PM8002 in small-cell lung cancer and triple-negative breast cancer. The bispecific antibody showed encouraging anti-tumor activity across various indications. BioNTech also progressed its mRNA cancer vaccine programs, with BNT111 meeting its primary efficacy endpoint in melanoma.BioNTech maintained a strong financial position with €17.8 billion in cash and investments as of Q3 2024. The company reaffirmed its R&D expense guidance of €2.4-2.6 billion while reducing SG&A expense guidance to €600-700 million and capital expenditure guidance to €300-400 million for 2024.

BioNTech reported Q3 2024 revenues of €1.2 billion, up from €895.3 million in Q3 2023, driven by earlier approvals of variant-adapted COVID-19 vaccines. Net profit reached €198.1 million with diluted EPS of €0.81. The company expects full-year 2024 revenues to be at the low end of €2.5-3.1 billion guidance range.The company advanced its oncology pipeline with multiple clinical trials, including two Phase 2 dose optimization studies for BNT327/PM8002 in small-cell lung cancer and triple-negative breast cancer. The bispecific antibody showed encouraging anti-tumor activity across various indications. BioNTech also progressed its mRNA cancer vaccine programs, with BNT111 meeting its primary efficacy endpoint in melanoma.BioNTech maintained a strong financial position with €17.8 billion in cash and investments as of Q3 2024. The company reaffirmed its R&D expense guidance of €2.4-2.6 billion while reducing SG&A expense guidance to €600-700 million and capital expenditure guidance to €300-400 million for 2024.